This article is more than 5 years old. Information may no longer be current.

New next-generation sequencing test launched for thyroid nodules

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference between benign and malignant genotypes of thyroid nodules, according to a release from the company.

The test, ThyGenX, can be used to help physicians reduce unnecessary surgery. Eight genes associated with papillary and follicular carcinoma make up the panel of genes tested.

“The launch of ThyGenX represents the next step in building Interpace Diagnostics’ emerging endocrine cancer test franchise,” Nancy Lurker, CEO of PDI, Inc., said in the release. “We are excited about the possibilities ahead as we continue to innovate and grow Interpace Diagnostics.”